ClinicalTrials.gov record
Completed Phase 3 Interventional

Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)

ClinicalTrials.gov ID: NCT01147939

Public ClinicalTrials.gov record NCT01147939. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 7, 2026, 9:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia

Study identification

NCT ID
NCT01147939
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Clavis Pharma
Industry
Enrollment
381 participants

Conditions and interventions

Interventions

  • Elacytarabine Drug
  • Investigator's Choice Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2010
Primary completion
Jan 31, 2013
Completion
May 31, 2013
Last update posted
Sep 26, 2013

2010 – 2013

United States locations

U.S. sites
23
U.S. states
16
U.S. cities
19
Facility City State ZIP Site status
Scripps Cancer Center Clinical Research La Jolla California 90095
USC/Norris Comprehensive Cancer Center and Hospital Los Angeles California 90033
UCLA School of Medicine, Division of Hematology/Oncology Los Angeles California 90095
Rocky Mountain Blood and Bone Marrow Transplant Program Denver Colorado 80218
Shands at the University of Florida Gainesville Florida 32610
Winship Cancer Institute at Emory Atlanta Georgia 30322
The Blood and Marrow Transplant Group of GA Atlanta Georgia 30342
Northwestern University Chicago Illinois 60611
Rush University Medical Center Chicago Illinois 60612
St. Francis Hospital and Health Center Indianapolis Indiana 46107
University of Iowa Hopsitals Iowa City Iowa 52242
LSU Health Sciences Center, Shreveport Louisiana 71103
Northern New Jersey Cancer Associates Hackensack New Jersey 07601
New York Presbyterian Hospital, Weill-Cornell Medical College New York New York 10021
Memorial Sloan-Kettering New York New York 10065
New York Medical College Valhalla New York 10595
Duke University Medical Center Durham North Carolina 27710
Wake Forest University, Health Sciences Section on Hematology and Oncology Winston-Salem North Carolina 27157-1082
The Jewish Hospital Cincinnati Ohio 45236
Western Pennsylvania Hospital Pittsburgh Pennsylvania 15224
St. Francis Hospital Greenville South Carolina 29601
Sarah Cannon Research Institute Nashville Tennessee 37203
Froedtert Hospital, Medical College of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01147939, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 26, 2013 · Synced May 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01147939 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →